trial

Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective

NCTId NCT02504476
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 52 (actual)
Sponsored by Amgen
Primary completion 2016-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
52 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2015-08
Primary completion
2016-02
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
AMG 581Midazolam

Sponsors

AmgenLead Sponsor

Sites

2 total
Glendale, United StatesGlendale, United States

Facts & assertions

4 sourced
Enrollment
52
Phase
PHASE1
Primary Completion Date
2016-02
Status
COMPLETED
relationships
The graph out of here
drug
AMG 581
drug
Midazolam
drug
lead_sponsor
Amgen
company
indication
Schizophrenia
indication
Schizophrenia or Schizoaffective Disorder
indication
Psychotic Disorders
indication